Recent Updates
Recently added Catalysts

Administration of a combination of treatments

Phase 2

Relapsed or Refractory Multiple Myeloma (RRMM) | Small molecule | Oncology |Bristol-Myers Squibb Company|Last Updated: Jan 16, 2026

Development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Jan 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

Clinical trial landscape

Administration of a combination of treatments · 1 trial · 1 indication

Phase 2 1
NCT07348393A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Relapsed or Refractory Multiple Myeloma (RRMM)
NOT YET_RECRUITING70 Analytics
PHASE2NOT YET_RECRUITING
A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma (RRMM)
NCT0734839370
Unlock trial analytics

Study Endpoints

Primary Endpoints

Determine the progression-free survival (PFS) of mezigdomide, carfilzomib and dexamethasone (480Kd) in participants with relapsed or refractory multiple myeloma (RRMM)
2 years

PFS defined as the time from inclusion to first documentation of progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma or death due to any cause, whichever occurs first.

Secondary Endpoints

Overall Survival (OS)
At 2-years
Best overall Response Rate (ORR)
2 years
Rate of very good partial response (VGPR) or better (VGPRR)
2 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Intervention (single arm)EXPERIMENTALAdministration of a combination of treatments : Mezigdomide / Carfilzomib / Dexamethasone

Interventions

NameTypeDescription
Administration of a combination of treatmentsDRUGAdministration of a combination of treatments : Mezigdomide / Carfilzomib / Dexamethasone
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Signed Written Informed Consent 2. Adult patients (≥18 years old) 3. ECOG Performance Status score of 0, 1, or 2. 4. Participant has documented diagnosis of multiple myeloma (MM) and measurable disease, defined as any of the following: 1. M-protein ≥ 0.5 g/dL by serum pro...

Countries:France
Unlock Eligibility Criteria

Competitive Landscape -Multiple Myeloma 222 trials (matched to "Relapsed or Refractory Multiple Myeloma (RRMM)")

Top 20 of 24 competitors

CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV16PHASE3Venetoclax, Etentamig, Elotuzumab, TNB-383B, ABBV-453
Bristol-Myers Squibb CompanyBMY18PHASE3Iberdomide, Lenalidomide, Mezigdomide, idecabtagene vicleucel, Arlocabtagene autoleucel
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK5PHASE3Gammagard Liquid, Ixazomib
GSK plc Sponsored ADRGSK17PHASE3Belantamab mafodotin, GSK3174998, Feladilimab, Dostarlimab, Belantamab
Johnson & JohnsonJNJ28PHASE3Talquetamab, Teclistamab, Bortezomib, Cilta-cel, Daratumumab
Regeneron Pharmaceuticals, Inc.REGN11PHASE3linvoseltamab, REGN17372, Fianlimab, Cemiplimab, REGN7945
Pfizer Inc.PFE11PHASE3Elranatamab, Axitinib, Bosutinib, Crizotinib, Palbociclib
Sanofi SA Sponsored ADRSNY17PHASE3Isatuximab, Pegenzileukin, SAR439459, Belumosudil, SAR446523
AstraZeneca PLCAZN5PHASE3AZD0120, GC012F, AZD0305
Gilead Sciences, Inc.GILD3PHASE3anitocabtagene-autoleucel
Karyopharm Therapeutics, Inc.KPTI7PHASE3Selinexor
Grifols, S.A. Sponsored ADR Class BGRFS1PHASE3Xembify
C4 Therapeutics, Inc.CCCC3PHASE2cemsidomide
Cellectar Biosciences, Inc.CLRB1PHASE2Iopofosine I-131
GeoVax Labs, Inc.GOVX1PHASE2GEO-CM04S1
Incyte CorporationINCY2PHASE1Ruxolitinib
Moderna, Inc.MRNA2PHASE1mRNA-2808
BeOne Medicines Ltd. Sponsored ADRONC1PHASE1Sonrotoclax
Caribou Biosciences, Inc.CRBU2PHASE1CB-011
Novartis AG Sponsored ADRNVS1PHASE2Dabrafenib, trametinib
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Bristol-Myers Squibb Company (BMY)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track